U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H13I3N2O2
Molecular Weight 597.9577
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPODIC ACID

SMILES

CN(C)C=Nc1c(cc(c(CCC(=O)O)c1I)I)I

InChI

InChIKey=YQNFBOJPTAXAKV-UHFFFAOYSA-N
InChI=1S/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C12H13I3N2O2
Molecular Weight 597.9577
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Iopanoic acid and ipodate salts have been used for oral cholangiography to visualize the biliary ducts. Ipodate salts have been used for the long-term treatment of Graves' disease and in hyperthyroidism. Ipodate reduced levels of T3 and T4 in the patients. Ipodate also inhibits the conversion of T4 to T3. It is not considered a first-line approach. Ipodate sodium lacks FDA approval for these uses. During investigation of mechanism of action was discovered, that binding of sodium ipodate with nuclear T3 receptors was not a prominent mechanism via which the drug attenuates T3 effects in vivo. Sodium ipodate could enhance T3 effects at the cellular level and that enhancement could not be reflected by routinely monitored serum TSH.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ORAGRAFIN SODIUM

Approved Use

Unknown

Launch Date

-2.37340803E11
Primary
ORAGRAFIN SODIUM

Approved Use

Unknown

Launch Date

-2.37340803E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
250 μM
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IPODIC ACID blood
Canis lupus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1600 μM × h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IPODIC ACID blood
Canis lupus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IPODIC ACID blood
Canis lupus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
A study of cardiac effects of thyroid hormones: evidence for amelioration of the effects of thyroxine by sodium ipodate.
1984 Jun
The use of oral radiographic contrast agents in the management of hyperthyroidism.
2001 Jun
Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis.
2003 Mar
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases.
2007 Jun
Patents

Patents

Sample Use Guides

hyperthyroidism: Oragrafin; 0.5 g, orally daily or every other day) for 15-60 day Graves' hyperthyroidism: 500 mg, orally, daily for 23-31 weeks
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:18:00 UTC 2021
Edited
by admin
on Fri Jun 25 23:18:00 UTC 2021
Record UNII
F604ZKI910
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IPODIC ACID
HSDB  
Common Name English
IPODATE [MI]
Common Name English
IOPODIC ACID [WHO-DD]
Common Name English
IOPODIC ACID
MART.   WHO-DD  
Common Name English
IPODIC ACID [HSDB]
Common Name English
IPODATE [VANDF]
Common Name English
IOPODIC ACID [MART.]
Common Name English
IPODATE
MI   VANDF  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28500
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
WHO-ATC V08AC10
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1474
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
EVMPD
SUB14257MIG
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
ECHA (EC/EINECS)
226-992-7
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
DRUG BANK
DB09333
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
RXCUI
5976
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY RxNorm
FDA UNII
F604ZKI910
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
MERCK INDEX
M6385
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY Merck Index
EPA CompTox
5587-89-3
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
HSDB
3347
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
NCI_THESAURUS
C76634
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
CAS
5587-89-3
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
PUBCHEM
5241
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
MESH
D007487
Created by admin on Fri Jun 25 23:18:00 UTC 2021 , Edited by admin on Fri Jun 25 23:18:00 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY